Xeris Biopharma Holdings, Inc. (XERS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Xeris Biopharma Holdings, Inc.
Address
1375 West Fulton Street
Chicago, IL 60607
United States of America (the)
Phone
844 445 5704
Website
Sector
Healthcare
Industry
Biotechnology
Employees
435
First IPO Date
June 21, 2018
Key Executives
| Name | Title | Pay | Year Born |
| John Shannon | Chairman & CEO | 1.36M | 1962 |
| Anh Nguyen | Chief Medical Officer | 653,703 | 1975 |
| Steven Pieper | Chief Financial Officer | 796,183 | 1977 |
| Beth Hecht | Chief Legal Officer & Corporate Secretary | 817,367 | 1964 |
| Kevin McCulloch | President & Chief Operating Officer | 913,527 | 1964 |
| Joshua Bennett | Vice President of Strategy & Business Development | 0 | N/A |
| Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | 0 | N/A |
| Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Kendal Korte | Senior Vice President of Human Resources | 0 | N/A |
Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
